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to view.Long-Term Outcomes After Transcatheter Aortic Valve Replacement in High-Risk Patients
With Severe Aortic Stenosis: The U.K. Transcatheter Aortic Valve Implantation Registry645Alison Duncan, Peter Ludman, Winston Banya, David Cunningham, Damian Marlee,
Simon Davies, Michael Mullen, Jan Kovac, Thomas Spyt, Neil MoatThe U.K. Transcatheter Aortic Valve Implantation Registry reported 30-day and 1-year mortality rates
of 7.1% and 21.4%, respectively. Duncan et al. studied 3- and 5-year outcomes in the same cohort of
patients. The minimal and maximal times from valve replacement were 4.1 years and 7.0 years,
respectively. The 3- and 5-year survival rates were 61.2% and 45.5%, respectively. Independent
predictors of mortality at 5 years were renal dysfunction, atrial ﬁbrillation, respiratory dysfunction,
ventricular dysfunction, coronary artery disease, and age. Periprocedural stroke was the only
independent procedural predictor of mortality. Device type, access route, and paravalvular leak did
not independently predict long-term outcome. Long-term survival after transcatheter aortic valve
replacement is largely determined by intrinsic patient factors.n EDITORIAL COMMENT
Is There Life After Transcatheter Aortic Valve Replacement? 654
Peter C. Block
European Experience With the Second-Generation Edwards SAPIEN XT Transcatheter
Heart Valve in Patients With Severe Aortic Stenosis: 1-Year Outcomes From the
SOURCE XT Registry657Gerhard Schymik, Thierry Lefèvre, Antonio L. Bartorelli, Paolo Rubino, Hendrik Treede,
Thomas Walther, Helmut Baumgartner, Stephan Windecker, Olaf Wendler, Philip Urban,
Lazar Mandinov, Martyn Thomas, Alec VahanianThe SOURCE XT Registry (Edwards SAPIEN XT Aortic Bioprosthesis Multi-Region Outcome Registry)
assessed post-market transcatheter use and 1-year clinical outcomes of the SAPIEN XT valve
(Edwards Lifesciences, Irvine, California) for 2,688 patients with severe aortic stenosis. The mean
age was 81.4  6.6 years, 42.3% were male, and the mean logistic EuroSCORE (European System
for Cardiac Operative Risk Evaluation) was 20.4  12.4%. The survival rate was 93.7% at 30 days
and 80.6% at 1 year. At 30 days, the stroke rate was 3.6%, the rate of major vascular complications
was 6.5%, the rate of life-threatening bleeding was 5.5%, the rate of new pacemakers was 9.5%,
and the rate of moderate/severe paravalvular leak was 5.5%. On multivariable analysis at 1 year,
nontransfemoral approach (hazard ratio [HR]: 1.84; p < 0.0001), renal insufﬁciency (HR: 1.53;
p < 0.0001), and liver disease (HR: 1.67; p ¼ 0.0453) had the 3 highest HRs. At 1 year, the safety
proﬁle was sustained and clinical beneﬁts established.
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APRIL 27, 2015 VOLUME 8, NUMBER 5Surgical Sutureless and Transcatheter Aortic Valves: Hemodynamic Performance
and Clinical Outcomes in Propensity Score-Matched High-Risk Populations With
Severe Aortic Stenosis670Vasileios Kamperidis, Philippe J. van Rosendael, Arend de Weger, Spyridon Katsanos,
Madelien Regeer, Frank van der Kley, Bart Mertens, Georgios Sianos,
Nina Ajmone Marsan, Jeroen J. Bax, Victoria DelgadoThe present report highlights the different hemodynamic performances of surgical sutureless and
transcatheter aortic valve prostheses by studying a propensity score 1:1–matched population who
underwent successful surgical sutureless or transcatheter aortic valve replacement (TAVR) for
severe aortic stenosis. Compared with sutureless valves, TAVR prostheses had larger effective
oriﬁce area index, lower pressure gradient, less frequent prosthesis-patient mismatch and low-ﬂow
state, but more frequent aortic regurgitation. The presence of prosthesis-patient mismatch was
independently associated with a low-ﬂow state at discharge and independently determined by
sutureless prostheses. However, the mid-term survival of patients treated with TAVR or sutureless
valves was comparable.n EDITORIAL COMMENT
The Ever-Increasing Choices for Aortic Valve Replacement: Which One Will Win
In the Marketplace?678Blase Carabello
Long-Term Outcomes of Percutaneous Paravalvular Regurgitation Closure
After Transcatheter Aortic Valve Replacement: A Multicenter Experience681Francesco Saia, Claudia Martinez, Sameer Gafoor, Vikas Singh, Cristina Ciuca,
Ilona Hofmann, Cinzia Marrozzini, John Tan, John Webb, Horst Sievert,
Antonio Marzocchi, William W. O’NeillSevere symptomatic paravalvular regurgitation (PVR) is a predictor of all-cause mortality after
transcatheter aortic valve replacement. There is limited experience with percutaneous
transcatheter closure of PVR, and the devices being used are adapted from other indications. In
this multicenter experience, Saia et al. evaluated the acute and long-term outcomes of 24 patients
(27 procedures) that required PVR closure after balloon-expandable or self-expandable
transcatheter aortic valve replacement. Different devices and strategies were used. Procedural
success was high (88.9%) and the reduction of PVR was durable. However, mortality rate during
follow-up was high, mainly due to noncardiac causes.n EDITORIAL COMMENT
Plugging Paravalvular Leaks After Transcatheter Aortic Valve Replacement:
Why and How?689John D. CarrollCONTINUED ON PAGE A-13
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APRIL 27, 2015 VOLUME 8, NUMBER 5Treatment of Acquired von Willebrand Syndrome in Aortic Stenosis With
Transcatheter Aortic Valve Replacement692Tobias Spangenberg, Ulrich Budde, Dimitry Schewel, Christian Frerker,
Thomas Thielsen, Karl-Heinz Kuck, Ulrich SchäferValvular aortic stenosis can cause an acquired von Willebrand syndrome by loss of high-molecular-
weight multimers (HMWM) and surgical aortic valve replacement has been shown to lead to factor
recovery. This study provides insights into the impact of transcatheter aortic valve replacement
(TAVR) on HMWM. Ninety-ﬁve consecutive patients underwent TAVR and hemostaseologic testing
at our institution. Forty-two percent of these patients experienced abnormal multimers but TAVR
led to a factor recovery proportional to the drop in mean pressure gradient. Bleeding and
transfusion requirement in TAVR patients was not associated with severe HMWM deﬁciency but
aortic regurgitation after TAVR adversely inﬂuenced HMWM recovery.n EDITORIAL COMMENT
Bleeding in Patients With Severe Aortic Stenosis in the Era of Transcatheter
Aortic Valve Replacement701Anetta Undas, Joanna Natorska
Clinical Outcomes and Revascularization Strategies in Patients With
Low-Flow, Low-Gradient Severe Aortic Valve Stenosis According to the
Assigned Treatment Modality704Crochan J. O’Sullivan, Lars Englberger, Nicola Hosek, Dik Heg, Davide Cao,
Giulio G. Stefanini, Stefan Stortecky, Steffen Gloekler, Ernest Spitzer, David Tüller,
Christoph Huber, Thomas Pilgrim, Fabien Praz, Lutz Buellesfeld, Ahmed A. Khattab,
Thierry Carrel, Bernhard Meier, Stephan Windecker, Peter WenaweserThe optimal treatment modality for patients with low ejection fraction, low-gradient (LEF-LG)
severe aortic stenosis (AS) and concomitant coronary artery disease (CAD) requiring
revascularization is unknown. A total of 204 patients with LEF-LG severe AS were allocated to
medical therapy (MT) (n ¼ 44), surgical aortic valve replacement (SAVR) (n ¼ 52), or transcatheter
aortic valve replacement (TAVR) (n ¼ 108). CAD complexity was assessed using the SYNTAX score,
and the primary endpoint was all-cause mortality at 1 year. Among LEF-LG patients, SAVR and
TAVR improved survival compared with MT. CAD severity was associated with worse outcomes and
incomplete revascularization predicted 1-year cardiovascular mortality among TAVR and SAVR
patients.
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APRIL 27, 2015 VOLUME 8, NUMBER 5Incidence and Predictors of Debris Embolizing to the Brain During Transcatheter
Aortic Valve Implantation718Nicolas M. Van Mieghem, Nahid El Faquir, Zouhair Rahhab, Ramón Rodríguez-Olivares,
Jeroen Wilschut, Mohamed Ouhlous, Tjebbe W. Galema, Marcel L. Geleijnse,
Arie-Pieter Kappetein, Marguerite E.I. Schipper, Peter P. de JaegereCerebrovascular embolization is frequent during transcatheter aortic valve replacement (TAVR). In
this study, 81 patients underwent TAVR with both balloon-expandable and self-expanding
transcatheter heart valves (THVs) and concomitant ﬁlter-based embolic protection. Filters were
retrieved after TAVR and sent for histopathological analysis. Debris was captured in 86% of
patients. Thrombotic material was found in 74% of patients and tissue-derived debris in 63%.
Tissue fragments were found more often with balloon-expandable THVs. The embolized tissue
originated from the native aortic valve leaﬂets, aortic wall, or left ventricular myocardium.
Balloon-expandable THVs and more oversizing were predictors of tissue embolization.n EDITORIAL COMMENT
Filtering the Truth Behind Cerebral Embolization During Transcatheter
Aortic Valve Replacement725Josep Rodés-Cabau, Rishi Puri
Thrombus Formation Following Transcatheter Aortic Valve Replacement 728
Eduardo De Marchena, Julian Mesa, Sydney Pomenti, Christian Marin y Kall,
Ximena Marincic, Kazuyuki Yahagi, Elena Ladich, Robert Kutys, Yaar Aga,
Michael Ragosta, Atul Chawla, Michael E. Ring, Renu VirmaniLimited cases of early transcatheter aortic valve dysfunction with rapid increase of transvalvular
aortic gradients following valve replacement have been described. Through reviews of the
published reports and 4 clinical cases, pathological and clinical ﬁndings of early valve thrombosis
are examined to elucidate methods for recognition and identifying potential causes and
treatments. Increasing transvalvular gradients on echocardiogram and return of symptoms may be
indicative of early valve thrombosis. Consideration should be given to treatment with dual
antiplatelet therapy and oral anticoagulation. Further research should be conducted to create
guidelines for antithrombotic therapy following transcatheter aortic valve replacement procedure.
Assessment of the Geometric Interaction Between the Lotus Transcatheter
Aortic Valve Prosthesis and the Native Ventricular Aortic Interface by
320-Multidetector Computed Tomography740Robert P. Gooley, James D. Cameron, Ian T. MeredithThe Lotus Valve System (Boston Scientiﬁc, Natick, Massachusetts) uses a unique mechanical
expansion and locking mechanism. This study used multidetector computed tomography imaging
to qualify and quantify the interaction between the Lotus device and the native aortic root anatomy.CONTINUED ON PAGE A-15
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Left Ventricular Assist Device: Friend or Foe750Michael Zacharias, Ravi Dhingra
Bail-Out Technique for Pulmonary Artery Rupture With a Covered Stent in
Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary
Hypertension752Kentaro Ejiri, Aiko Ogawa, Hiromi Matsubara
Transesophageal Echocardiography–Guided Percutaneous Intervention for
a Mitral Valve Leaﬂet Perforation754Rajiv Goswami, Barker Colin, Matthew Jackson, Neal Kleiman, Stephen Little
n ONLINE FEATURE Overestimation of Paravalvular Leak With Edwards SAPIEN 3
Transcatheter Aortic Valve Replacemente69Taisei Kobayashi, Jay Giri, Prashanth Vallabhajosyula, Howard C. Herrmann,
Dinesh H. Jagasia
n ONLINE FEATURE Double Trouble: Percutaneous Disobstruction of
2 Pulmonary Veins Following Catheter Ablation for Atrial Fibrillatione73Michele Coceani, Gennaro Santoro, Marcello Piacenti, Umberto Startari,
Bruno Formichi, Cataldo Palmieri, Sergio Berti
n ONLINE FEATURE A Man With 3 Lives: Long-Term Follow-Up Following
Percutaneous Closure of Left Ventricular Pseudoaneurysm Necke77Jonathon M. White, Boris S. Lowe, Peter N. Ruygrok
n ONLINE FEATURE Percutaneous Intervention to Large Left Anterior Descending
Artery Fistula Post–Right Ventricular Biopsy in a Transplant Recipiente81Chris Anthony, Roberto Spina, Meenal Sharma, Christopher Hayward,
Anne Keogh, Peter Macdonald, David Roy
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